Cargando…

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173730/ https://www.ncbi.nlm.nih.gov/pubmed/37097712 http://dx.doi.org/10.1182/bloodadvances.2023010152

Ejemplares similares

Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
por: Sitenga, Jenna, et al.
Publicado: (2018)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
por: van Rhee, Frits, et al.
Publicado: (2015)

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
Publicado: (2022)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Publicado: (2023)

Emerging treatments in Castleman disease – a critical appraisal of siltuximab
por: Koff, Jean L, et al.
Publicado: (2016)

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
por: Chrysochoou, Stamatios, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

Crouch S, Painter D, Barrans SL, et al. Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network. Blood Adv. 2022;6(21):5716-5731.
Publicado: (2023)

Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
Publicado: (2023)

Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022;6(17):5160-5164.
Publicado: (2023)

Nawas MT, Sanchez-Escamilla M, Devlin SM, et al. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022;6(22):5898-5907.
Publicado: (2023)

Kudo K, Kubota Y, Toki T, et al. Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Adv. 2022;6(10):3162-3166.
Publicado: (2022)

Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Publicado: (2022)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Erratum to “Cardiac Damage Staging Classification in Asymptomatic Moderate or Severe Primary Mitral Regurgitation”: [Structural Heart 2022;6(1):100004]
Publicado: (2023)

Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Publicado: (2023)

Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Publicado: (2023)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
Publicado: (2023)

Aiello S, Gastoldi S, Galbusera M, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv. 2022;6(3):866-881.
Publicado: (2022)

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2015)

Development and Validation of a Screening Scale for Depression in Korea: The Lee and Rhee Depression Scale
por: Hwang, Seon Hee, et al.
Publicado: (2012)

POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation
por: Lee, Yong-Moon, et al.
Publicado: (2022)

Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. (2022);6(1):327-338.
Publicado: (2023)

Melkersson-Rosenthal syndrome
por: Desai, Soaham Dilip, et al.
Publicado: (2014)

Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
Publicado: (2022)

Syndrome de Melkersson-Rosenthal
por: Mahfoudhi, Madiha, et al.
Publicado: (2015)

Melkersson-Rosenthal syndrome of the vulva
por: Aukerman, Erica, et al.
Publicado: (2022)

Eshel A, Sharon I, Nagler A, et al. Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. Blood Adv. 2022;6(2):568-573.
Publicado: (2022)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022;6(11):3220-3229.
Publicado: (2022)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Charles H. Rosenthal, D.D.S.
Publicado: (1914)

Siltuximab (CNTO 328): a promising option for human malignancies
por: Chen, Runzhe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ippej5dqi4acgi7drtp6fom48u